Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease
Abstract Schizophrenia is a debilitating condition necessitating more efficacious therapies. Previous studies suggested that schizophrenia development is associated with aberrant synaptic pruning by glial cells. We pursued an interdisciplinary approach to understand whether therapeutic reduction in glial cell—specifically astrocytic—phagocytosis might benefit neuropsychiatric patients. We discovered that beta-2 adrenergic receptor (ADRB2) agonists reduced phagocytosis using a high-throughput, phenotypic screen of over 3200 compounds in primary human fetal astrocytes. We used protein interaction pathways analysis to associate ADRB2, to schizophrenia and endocytosis. We demonstrated that patients with a pediatric exposure to salmeterol, an ADRB2 agonist, had reduced in-patient psychiatry visits using a novel observational study in the electronic health record. We used a mouse model of inflammatory neurodegenerative disease and measured changes in proteins associated with endocytosis and vesicle-mediated transport after ADRB2 agonism. These results provide substantial rationale for clinical consideration of ADRB2 agonists as possible therapies for patients with schizophrenia..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Discover mental health - 3(2023), 1 vom: 30. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bowen, Ellen R. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s44192-023-00050-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053931483 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053931483 | ||
| 003 | DE-627 | ||
| 005 | 20231201064657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231201s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s44192-023-00050-5 |2 doi | |
| 035 | |a (DE-627)SPR053931483 | ||
| 035 | |a (SPR)s44192-023-00050-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bowen, Ellen R. |e verfasserin |0 (orcid)0000-0001-8089-0944 |4 aut | |
| 245 | 1 | 0 | |a Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Abstract Schizophrenia is a debilitating condition necessitating more efficacious therapies. Previous studies suggested that schizophrenia development is associated with aberrant synaptic pruning by glial cells. We pursued an interdisciplinary approach to understand whether therapeutic reduction in glial cell—specifically astrocytic—phagocytosis might benefit neuropsychiatric patients. We discovered that beta-2 adrenergic receptor (ADRB2) agonists reduced phagocytosis using a high-throughput, phenotypic screen of over 3200 compounds in primary human fetal astrocytes. We used protein interaction pathways analysis to associate ADRB2, to schizophrenia and endocytosis. We demonstrated that patients with a pediatric exposure to salmeterol, an ADRB2 agonist, had reduced in-patient psychiatry visits using a novel observational study in the electronic health record. We used a mouse model of inflammatory neurodegenerative disease and measured changes in proteins associated with endocytosis and vesicle-mediated transport after ADRB2 agonism. These results provide substantial rationale for clinical consideration of ADRB2 agonists as possible therapies for patients with schizophrenia. | ||
| 700 | 1 | |a DiGiacomo, Phillip |4 aut | |
| 700 | 1 | |a Fraser, Hannah P. |0 (orcid)0000-0002-3733-5459 |4 aut | |
| 700 | 1 | |a Guttenplan, Kevin |0 (orcid)0000-0003-4242-4349 |4 aut | |
| 700 | 1 | |a Smith, Benjamin A. H. |0 (orcid)0000-0001-8802-416X |4 aut | |
| 700 | 1 | |a Heberling, Marlene L. |0 (orcid)0000-0002-2316-9349 |4 aut | |
| 700 | 1 | |a Vidano, Laura |0 (orcid)0000-0002-9473-7913 |4 aut | |
| 700 | 1 | |a Shah, Nigam |0 (orcid)0000-0001-9385-7158 |4 aut | |
| 700 | 1 | |a Shamloo, Mehrdad |4 aut | |
| 700 | 1 | |a Wilson, Jennifer L. |0 (orcid)0000-0002-2328-2018 |4 aut | |
| 700 | 1 | |a Grimes, Kevin V. |0 (orcid)0000-0003-2469-2366 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Discover mental health |d [Cham] : Springer International Publishing, 2021 |g 3(2023), 1 vom: 30. Nov. |w (DE-627)SPR04514060X |w (DE-600)3097626-1 |x 2731-4383 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2023 |g number:1 |g day:30 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s44192-023-00050-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2023 |e 1 |b 30 |c 11 | ||